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Background: Injuries to the brain promote upregulation of prostaglandins, notably the proinflammatory PGF2α, and
overactivation of their cognate G-protein-coupled FP receptor, which could exacerbate neuronal damage. Our study
is focused on investigation of the FP receptor as a target for novel neuroprotective drugs in a preclinical animal
traumatic brain injury (TBI) model.
Methods: Accordingly, the effects of acute intraperitoneal post-treatment with selective FP antagonist AL-8810
were studied in wildtype (WT) and FP receptor knockout (FP−/−) mice after controlled cortical impact (CCI).
Neurological impairments were evaluated using neurological deficit scores (NDS) and the grip strength test. Cortical
lesions and overall brain pathology were assessed using immunohistochemistry.
Results: Morphological analyses of cerebral vasculature and anastomoses revealed no differences between WT and
FP−/− mice. CCI produced cortical lesions characterized by cavitation, neuronal loss, and hematoma with a volume
of 20.0 ± 1.0 mm3 and significant hippocampal swelling (146.5 ± 7.4% of contralateral) compared with sham
(P < 0.05). Post-treatment with AL-8810 (1 to 10 mg/kg) had no significant effect on cortical lesions, which suggests
the irreversible effect of primary CCI injury, but significantly reduced hippocampal swelling to a size not significantly
different from the sham group. Post-treatment with AL-8810 at a dose of 10 mg/kg significantly improved NDS at
24 and 48 hours after CCI (P < 0.001 and P < 0.01, respectively). In the AL-8810 group, CCI-induced decrease in grip
strength was three-fold (2.93 ± 1.71) less and significantly different than in the saline-treated group. The FP−/− mice had
significantly less hippocampal swelling, but not NDS, compared with WT mice. In addition, immunohistochemistry
showed that pharmacologic blockade and genetic deletion of FP receptor led to attenuation of CCI-induced gliosis and
microglial activation in selected brain regions.
Conclusion: This study provides, for the first time, demonstration of the unique role of the FP receptor as a potential
target for disease-modifying CNS drugs for treatment of acute traumatic injury.
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Traumatic brain injury (TBI) is among the major causes
of death and disability in the United States and current
treatment is limited to supportive care. TBI is a complex
disorder including four main pathological sequelae: con-
tusions, diffuse axonal injury, hematoma, and subarach-
noid hemorrhage causing secondary biochemical and
metabolic changes that contribute to neuronal death [1].
Secondary brain injury involving excitotoxicity, oxidative
stress, and neuroinflammation and edema plays a key
role in the neurological outcome of TBI survivors [2].
Although the secondary injury following TBI is poten-
tially treatable, there is no effective treatment currently
available, and the discovery of new targets for TBI thera-
peutics remains critical. A few anti-inflammatory path-
ways are currently considered as a promising approach
in TBI [3]. Furthermore, most of the therapeutic agents
currently considered for TBI translation exhibit direct or
indirect anti-inflammatory actions [4]. A growing body
of experimental and clinical evidence suggests that the
inducible cyclooxygenase-2 (COX-2) and prostaglandin
synthetase enzymes play an important role in the neuroin-
flammatory cascades associated with neurotoxicity and
neuronal damage during brain insults [5-8]. Increased
COX-2 immunoreactivity has been demonstrated in
microglia and neurons of the ischemic neonatal and adult
human brain [9-11]. In addition, COX-2 upregulation has
been reported in the cortex and hippocampus after experi-
mental TBI, and this upregulation was associated with
neuronal death [12-16]. Experimental evidence also has
demonstrated that brain trauma causes an increased re-
lease of arachidonic acid, a COX-2 substrate involved in
prostaglandin production [17,18]. Although COX-2 inhib-
ition could be beneficial in TBI [12,14-16,19], clinical
application of COX-2 inhibitors might be limited because
of cardiovascular side effects [20]. Further studies on the
downstream effectors of COX-2, such as prostaglandins
and their respective receptors, have been previously been
conducted and suggested that the certain prostaglandin
receptor antagonists could be used as an alternative to
COX-2 inhibitors [8]. Activation of several subtypes of
prostaglandin receptors leads to increased intracellular
calcium and neurotoxicity. The effects of PGF2α are me-
diated via activation of its specific G-protein-coupled
receptor, the FP receptor, and would result in neuronal
intracellular calcium overload [21]. The roles of COX-2
and some prostaglandins are understood in stroke models
[7,8,21,22]; however, the effect of PGF2α and its FP recep-
tor are not understood in TBI.
With the known physiological role of the FP receptor
in calcium signaling [6,21], we hypothesized that
changes in levels of PGF2α, due to increased COX-2 ac-
tivity, and subsequent FP receptor overactivation may
contribute to excitotoxic, hypoxic, and hemorrhagicdamage [7]. Hence, our study was focused on the inves-
tigation of the FP receptor as a target for TBI drugs
using its selective antagonist and FP receptor knockout
(FP−/−) mice in a controlled cortical impact (CCI)
model. Based on our preliminary data indicating that
FP−/− mice have significantly reduced infarct volume
following stroke [21,22], we have tested whether genetic
deletion of the FP receptor or its pharmacologic block-
ade with the selective antagonist AL-8810 [23] would
limit brain damage and neurological outcome following
brain trauma.Methods
Animals
All animal protocols were approved by the University of
Florida Animal Care and Use Committee. A total of 83
male wildtype (WT) and 20 male FP receptor knockout
(FP−/−) C57BL/6 mice aged 2.0 ± 1.1 and 4.2 ± 1.5 months,
respectively, was used. The mean body weight of WT and
FP−/− mice used for CCI was 23.3 ± 1.5 (n = 75) and 21.8 ±
3.9 g (n = 17), respectively.CCI procedures
CCI in mice was produced using PCI3000 PinPoint Pre-
cision Cortical Impactor (Hatteras Instruments, Cary,
NC, USA) and a stereotaxic apparatus (David Kopf
Instruments, Tujunga, CA, USA). Prior to all proce-
dures, anesthesia was induced with 4% isoflurane in a
25% oxygen-in-air mixture. During all surgical pro-
cedures, mice were maintained on 2% isoflurane
anesthesia via nose cone, and body temperatures were
monitored using a rectal probe and were maintained
with a controlled heating pad (Fine Science Tools,
Vancouver, BC, Canada). After the skull was exposed
with a central skin incision and soft tissue was removed
with a cotton tip, a circular craniotomy of approxi-
mately 4 mm in diameter was made in the middle of the
right parietal bone, about 0.5 mm from sagittal, coronal,
and lambdoid sutures, leaving the dura intact under
visual control using an Olympus SZ61 dissecting micro-
scope (Olympus Corporation, Tokyo, Japan). The CCI
parameters were as follows: impact tip diameter 3 mm,
velocity 3 m/s, compression time 100 ms, and a com-
pression distance of 1 mm. These parameters allow to
produce experimental TBI of mild-to-moderate severity
based on anatomical and neurobehavioral outcomes [24].
Sham mice underwent craniotomy only. After surgical
procedures, the incision was closed using Reflex 7 skin
closure system (CellPoint Scientific, Inc., Gaithersburg,
MD, USA), each mouse received an intraperitoneal injec-
tion of warm saline to prevent dehydration, and the mice
were transferred to a temperature-controlled recovery
chamber for at least one hour.
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In single regiment groups, AL-8810 (Cayman Chemical
Co., Ann Arbor, MI, USA) was injected intraperitoneally
after completion of all surgical procedures at two doses: 1
and 10 mg/kg. The animals with repeated treatment re-
ceived three injections of AL-8810 at 10 mg/kg each.
AL-8810 injections were done directly after surgery and at
24 and 48 hours. To perform the second and third injec-
tions, mice were briefly anesthetized with isoflurane to
avoid potential injury to the surgery site due to handling.
AL-8810 was dissolved in dimethyl sulfoxide at a concen-
tration of 25 mg/mL, aliquoted, and stored at −20°C. Solu-
tions for AL-8810 injection 25 or 250 μg/mL for AL-8810
doses of 1 and 10 mg/kg, respectively, were prepared in
saline immediately before use.
Neurological deficit scores (NDS)
Neurological function was assessed using a comprehen-
sive 24-point NDS, slightly modified from Clark and col-
leagues [25]. The assessment included six individual
tests, and each test was scored from 0 for normal per-
formance up to 4 points with increasing severity, as
summarized in Table 1. The sum of scores from the in-
dividual tests was reported as the NDS. All scoring was
performed at the time of test and was verified offline
using video recordings. The NDS was assessed at least at
24 hours after termination of anesthesia in single and re-
peated drug- or saline-treatment groups. No detectable
differences were observed between saline-treated sham
groups with single and repeated treatments, indicating
that brief anesthesia had no effect on NDS; thus, the
NDS data from saline-treated treated mice that under-
went CCI were pooled together.
Grip strength test
Forelimb strength measurements in mice were carried
out using the Animal Grip Strength System (San Diego
Instruments, San Diego, CA, USA). The mouse was placedTable 1 Neurological deficit scoring
Test Body
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to prevent faover the grid by the tail so that its forepaws were allowed
to grasp the steel bar and it was then pulled backward
until the grip was released. Each test consisted of three
consecutive trials. Between trials, each mouse was allowed
to rest for one minute. The data were reported as the aver-
age value of maximal force recorded before the mouse re-
leased the bar. Baseline grip strength values were obtained
in each animal one day before CCI or sham procedure.
Histological procedures and analyses
Mice were euthanized and transcardially perfused with
4% paraformaldehyde in PBS. Brains were removed,
post-fixed with the perfusion solution, and incubated for
at least 24 hours in 30% sucrose/PBS solution. A series
of eight 30-μm thick coronal sections were obtained
throughout the entire brain and processed for histo-
logical analysis. To quantitate brain pathology, cresyl
violet staining was used. Cortical infarct volume was
quantified using a slightly modified procedure described
elsewhere [26]. Briefly, cortical lesion volume was calcu-
lated from injured areas located and measured in eight
brain sections spaced within 0.5 mm apart from the
same animal. The lesions characterized by cavitation,
neuronal loss, and hematoma. These cresyl violet-
stained slides were also used for assessment of hippo-
campal edema. Hippocampal swelling was quantified
using three brain sections from the same slides between
1 and 2 mm posterior to the bregma, representing in-
jured brain regions within midline of focal impact. The
areas of hippocampi in each hemisphere were measured
and presented as the mean ratio between values of ipsi-
lateral to contralateral sides. Immunohistochemistry for
ionized calcium-binding adapter protein 1 (Iba1) and glial
fibrillary acidic protein (GFAP) immunohistochemistry
were performed using polyclonal rabbit anti-Iba1 (1:1,000
dilution; Wako Bioproducts, Richmond, VA, USA) and
anti-GFAP (1:2,000 dilution; DAKO, Carpinteria, CA,
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tion; BA-500, Vector Laboratories, Burlingame, CA, USA),
and Vectastain ABC and DAB SK-4100 kits (Vector
Laboratories, Burlingame, CA, USA) according to the
manufacturer’s instructions. All slides were scanned using
ScanScope CS (Aperio Technologies, Inc., Vista, CA,
USA) and analyzed using ImageScope software (Aperio
Technologies, Inc., Vista, CA, USA).
Visualization of vasculature and analysis of anastomosis
Mice were deeply anesthetized with a lethal dose of iso-
flurane and were perfused via the left ventricle with 5 mL
of cold PBS, followed by 1 mL of black latex paint with
flow rates not to exceed 1 mL/min. The brains were post-
fixed in 10% paraformaldehyde for 24 hours at 4°C prior
to imaging of the dorsal cortical surface. Images of the
dorsal surface were obtained using a desktop endoscope/
microscope. Anastomosis of the cortical surface was deter-
mined by tracing the distal branches of the anterior cere-
bral artery (ACA) and middle cerebral artery (MCA) to
the point of anastomosis. The point of anastomosis was
defined as the narrowest point along the vessel connecting
the ACA and MCA, or halfway between the nearest
branch points [27]. Each anastomosis was marked with a
dot. All anastomoses were connected with a line to form
the line of anastomosis. Next, the distance from the mid-
line was determined by measuring, from the midline to
the line of anastomosis, every millimeter from the frontal
pole to the end of the cerebral cortices [28].
Statistical analyses
The statistical comparisons among multiple groups were
done using one-way ANOVA followed by Tukey's multiple
comparison test. Differences between two groups were de-
termined by two-tailed paired or unpaired Student’s
t-tests. Normality assumption testing was performed
using the Kolmogorov-Smirnov test. If data were non-
parametric by nature (for example, data were already or-
dered according to qualitative ranks such as NDS), the
Kruskal-Wallis ANOVA on ranks sum test was used to
compare differences between multiple groups and the
Wilcoxon rank sum test was used to compare differences
between two groups to compare measurements before
and after an intervention (that is, single and repeated drug
treatments) in the same animals. Data are presented as the
mean ± standard error or mean ± standard deviation and
P < 0.05 was considered as statistically significant [29].
Results
Effect of selective FP antagonist AL-8810 on the anatomical
outcomes
To determine the effects of CCI in all experiments, the
treated animals were compared with sham-operated ani-
mals that had undergone craniotomy only. To evaluatethe FP receptor as a novel target, selective FP receptor
antagonist AL-8810 was administered intraperitoneally
within ten minutes after CCI, as we previously did in
ischemic stroke models [21,22].
To determine if the FP receptor blockade will improve
short-term anatomical outcome following CCI, brain sec-
tions were analyzed 48 hours after surgery. Mice were ran-
domly assigned to four groups: sham, CCI saline control,
and two AL-8810 treatment groups with doses of 1 and
10 mg/kg. At the 48-hour time point, CCI caused complex
cortical lesions, including hematoma, decrease in cellular
density in surrounding areas, and loss of cortical tissues
referred to as cavitation. In saline-treated animals, CCI
caused cortical injury with a relative volume of 20.0 ±
1.0 mm3, whereas no detectable cortical injury was ob-
served in sham animals. Acute post-treatment with AL-
8810 at both doses had no significant effect on cortical le-
sions, which suggests the irreversible effect of primary
mechanical CCI injury. Also, AL-8810 did not cause any
detectable changes in brain morphology in the sham ani-
mals (n = 3, Additional file 1: Figure S1A). In addition to
cortical injury, significant hippocampal swelling (146.5 ±
7.4% of contralateral) was observed in all saline-treated
CCI animals compared with sham (P < 0.05, n = 4). Post-
treatment with AL-8810 at both doses reduced CCI-
induced hippocampal swelling to levels not significantly
different from the sham group (Figure 1, A and B). How-
ever, a significant difference between AL-8810- and saline-
treated animals that underwent CCI was observed only at
a dose of 10 mg/kg. To test whether the beneficial effects
of a single post-treatment with AL-8810 (10 mg/kg) fol-
lowing CCI would be sustained for extended time periods,
anatomical assessments were performed ten days after in-
jury. To test whether repeated AL-8810 treatment would
have additional benefits, this compound was administered
at a dose of 10 mg/kg three times in a separate group. In
this treatment group, the first AL-8810 injection was ad-
ministered post-CCI, as in the single treatment group, and
then two additional injections were given once a day dur-
ing the next two days. At this late time point in the CCI
group, the lesions were characterized by structurally de-
fined cortical cavitation (Figure 1, C and D) and the sig-
nificant hippocampal swelling was still present, though it
was less prominent compared with the 48-hour time
point. Ten days after injury, hippocampal swelling in
the CCI group had a value of 126.39 ± 4.110 (n = 8) of
the contralateral side and was significantly lower than the
value at the 48-hour time point (P < 0.05, Student
independent t-test between two CCI groups). Post-
treatment with AL-8810 using both treatment regi-
ments showed a tendency to decrease the CCI-induced
hippocampal swelling to levels not significantly different
from the sham group; however, there was no significant




























































































Figure 1 Brain pathology after controlled cortical impact (CCI): the effect of FP receptor blockade. (A) Representative photographs of
cresyl violet-stained brain sections from sham and CCI-injured WT mice demonstrating cortical injury and hippocampal swelling in the areas
between bregma one and two 48 hours after injury. (B) Quantitative analysis of the hippocampal area demonstrating a significant increase in
relative hippocampal areas normalized to contralateral side in the ipsilateral hemisphere and significant decrease of hippocampal swelling in
AL-8810- (10 mg/kg) treated mice 48 hours after CCI. (C) Representative photographs of cresyl-violet stained brain sections from sham and
CCI-injured WT mice demonstrating cortical cavitation and remaining hippocampal swelling in the areas ten days after injury. (D) Quantitative
analysis of relative hippocampal areas normalized to the contralateral side in saline- and AL-8810- (10 mg/kg) treated WT mice that underwent
CCI or sham. The data demonstrate a significant hippocampal swelling ten days after injury compared with sham group, whereas there are no
significant differences between relative hippocampal area values between two treatment groups that underwent CCI, between sham and either
of these treatment groups, or between CCI groups with saline and drug treatments. Data are presented as mean ± SEM, *P < 0.05, **P < 0.01,
versus saline-treated sham group, and #P < 0.05, versus saline-treated CCI group, one-way ANOVA followed by Tukey's multiple comparison test
(n = 7 to 9).
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underwent CCI.
Effect of selective FP antagonist AL-8810 on the
neurobehavioral outcomes
Neurobehavioral assessment was performed at 24 and
48 hours after CCI or sham. CCI caused marked neuro-
logical impairment in saline-treated CCI mice as reflected
in increased NDS, whereas no or only marginal neuro-
logical symptoms were observed in the sham animals.
Figure 1A demonstrates a significant neurological impair-
ment following CCI at the 24- and 48-hour time points
compared with sham animals. The NDS in CCI animals
was not significantly different between the two tested time
points. Our data indicate that a single post-treatment with
AL-8810 at a dose of 10 mg/kg significantly improved the
NDS at both tested time points 24 and 48 hours after CCI,whereas the effect of a single 1 mg/kg dose was not signifi-
cant (Figure 2A). To determine if repeated treatment with
AL-8810 would have additional benefits compared with a
single treatment, a separate group of mice that had NDS
assessed at 24 hours and that had received one treatment
immediately after CCI were given an additional treat-
ment 24 hours after CCI and the first NDS assessment
according to the repeated treatment protocol used in
this study, and the NDS in these mice was assessed sec-
ond time at 48 hours after CCI (Figure 2B). The data
demonstrated that following a second AL-8810 treat-
ment, NDS values were not further improved compared
with a single treatment.
The grip test was used as an additional test to assess
neuromuscular function following CCI by measuring
maximal muscle strength of forelimbs as a primary
















































Figure 2 FP receptor blockade improves behavioral outcomes after controlled cortical impact (CCI). (A) Neurological deficit scores (NDS)
in CCI-injured WT mice 24 and 48 hours after injury. Post-treatment AL-8810 (10 mg/kg) significantly improved NDS at both time points,
**P < 0.01, ***P < 0.001, Kruskal-Wallis ANOVA on ranks followed by Dunn's multiple comparison test (n = 5 to 9). (B) Comparison of NDS
between a single dose of AL-8810 (10 mg/kg) 24 hours after injury and two doses of AL-8810 (10 mg/kg, once a day) 24 and 48 hours after injury
in the same mice that underwent CCI. The data were obtained in a separate cohort of mice. ‘ns’ denotes not statistically different, Wilcoxon
matched-pairs signed rank test (P = 0.6, n = 8). (C) Changes in grip strength in CCI-injured WT mice 24 and 48 hours after injury. Post-treatment
AL-8810 (10 mg/kg) significantly improved CCI-induced impairment in grip strength at 24 hours. *P < 0.05, paired Student’s t-test versus baseline.
#P < 0.05, one-way ANOVA followed by Tukey's multiple comparison test, n = 3 in each group.
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out before the CCI procedure and 24 and 48 hours after
CCI (Figure 2C). The mice were randomly divided in
two groups: control and experimental. The average base-
line values were 186.11 ± 3.89 g and 193.67 ± 10.65 g in
control and experimental groups, respectively, and these
values were not significantly different (data presented as
mean ± standard deviation, P = 0.3, independent Stu-
dent’s t-test, n = 3 in each group). Both groups were
subjected to CCI, and the experimental group received
single intraperitoneal injections of AL-8810 at a dose of
10 mg/kg, whereas the control group received single in-
jections of saline. CCI caused a significant decrease in
the grip strength 24 hours post-CCI in the saline-treated
group, but to a significantly lesser extent in the AL-8810-treated group compared with the corresponding baseline
values in these groups. This experiment showed that in
the AL-8810-treated animals 24 hours after CCI, the de-
crease in the grip strength was significantly improved to
about 50% of the value observed in saline-treated animals,
although at 48 hours, the changes in grip strength values
were no longer significantly different.
Effect of FP receptor knockout anatomical and
neurobehavioral outcomes following CCI
Based on our published data demonstrating the neuropro-
tective effect of genetic FP receptor deletion in ischemic
stroke models [21,22], we have tested this hypothesis to
see if similar improvement could be achieved in the TBI

















































Figure 3 Distance from the midline and number of
anastomoses in wildtype (WT) and FP receptor knockout (FP−/−)
mice. (A) Representative photographs of cortical surface of brains
from WT and FP−/− mice perfused with black latex paint. Yellow
lines and black dots illustrate lines and points of anastomosis. Bar
graphs represent mean values of total number of anastomoses for
both hemispheres (B) and mean distances from midline (C) in WT
(n = 9) and FP−/− (n = 6) mice. Data presented as mean ± standard
deviation. No significant differences were observed between the
values in WT and FP−/− mice when using unpaired Student’s t-test.
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cresyl violet staining on 30-μm cryostat brain sections,
and behavioral outcomes were assessed using NDS.
Based on the data that strain-dependent variability in
cerebral vascular anatomy might be associated with dif-
ferent susceptibility to cerebral ischemia [30], and know-
ing the importance of vascular damage in TBI, we
looked at anatomical differences between WT and FP−/−
mice in the major cortical arteries that might potentially
affect outcome in the CCI model. Detailed morpho-
logical analysis of ACA and MCA using black latex paint
showed that there were no significant differences in total
numbers of anastomoses and the location of the line of
anastomosis between the two groups (Figure 3).
Hippocampal swelling in FP−/− mice that underwent
CCI were not significantly different from sham FP−/− ani-
mals. However, hippocampal swelling was significantly
lower compared with saline-treated WT mice from the
CCI group. Post-treatment with 10 mg/kg AL-8810 also
had no additional effect. In addition, a group of FP−/− mice
were post-treated with AL-8010 to test the specificity of
the protective effect of this drug candidate (Figure 4, A
and B). No significant differences in anatomical outcomes
between AL-8010 and saline treatments were observed in
the FP−/− mice.
Also, when using severe CCI parameters, NDS 24 and
48 hours after injury was not significantly different be-
tween saline-treated WT and FP−/− mice (Figure 4C). In
the FP−/− mice, post-treatment with AL-8810 at the
highest dose of 10 mg/kg also had no significant effect
on the NDS.
Effect of selective FP antagonist AL-8810 on the microglial
activation and astrogliosis following CCI
Knowing the important role of microglia and astrocytes
in TBI [31], to investigate putative protective mecha-
nisms of AL-8810 in the brain, we performed immuno-
histochemical studies to detect changes in the brain
levels of microglial and astrocytic markers in WT mice
48 hours and 10 days following injury. In addition, to
study the role of the FP receptor in the brain following
brain injury, and possible involvement of this receptor in
microglial activation and astrogliosis, the changes in the
brain levels of microglial and astrocytic markers were stud-
ied in the FP−/− mice 48 hours after CCI, similar to that of
the WT mice. Forty-eight hours after injury, CCI caused
apparent microglial activation detected as increased Iba1
immunoreactivity in the surrounding areas of cortical in-
jury, referred to as a penumbra, as well as in the ipsilateral
hippocampus and some thalamic regions within lateral
dorsal and posterior nuclei compared to corresponding
contralateral areas. In the CCI-injured animals, increased
Iba1 immunoreactivity was accompanied by morphological
changes in the immunopositive cells. Figure 5A showsmicrophotographs that represent typical morphological
changes in the Iba1-positive cells in the hippocampus, sug-
gesting activation of microglia in the ipsilateral compared
with contralateral area. A slight increase was shown in
Iba1 levels in the ipsilateral cortical area surrounding cra-
niotomy, but not in other brain regions, and was also ob-
served in sham animals. However, the changes in the Iba1
levels in sham animals were substantially lower than in the
cortical penumbra of the animals from the CCI group. In
the AL-8810-treated animals, the morphological changes
in the microglia were less strongly pronounced than in the
saline-treated group. However, no statistical differences be-
tween relative immunoreactivities, normalized to the cor-
responding areas in the contralateral side, were detected
between these two groups at 48 hours (Figure 5C). No
apparent changes in the Iba1 immunoreactivity were ob-
served between contralateral sides of sham- and CCI-
treated FP−/− mice (Figure 5B). Ten days after injury, Iba1

































































Figure 4 The effects of FP receptor deletion on the anatomical and behavioral outcomes after controlled cortical injury (CCI).
(A) Representative photographs of cresyl violet-stained brain sections between 1 and 2 mm posterior from bregma from sham- and CCI-injured
FP−/− mice 48 hours after injury. (B) Quantitative analysis of related hippocampal areas normalized to contralateral side in sham, and saline- and
AL-8810- (10 mg/kg) treated mice that underwent CCI. Data are presented as mean ± SEM, **P < 0.01, versus saline-treated WT sham group, and
#P < 0.05, versus saline-treated WT CCI group. ‘ns’ denotes not statistically different, one-way ANOVA followed by Tukey's multiple comparison test
(n = 4 to 9). (C) Neurological deficit scores (NDS) in CCI-injured FP−/− mice in comparison with WT mice 24 and 48 hours after injury.
Post-treatment with AL-8810 (10 mg/kg) had no significant effect on NDS in CCI-injured saline or AL-8810-treated FP−/− mice; there was also no
significant difference between FP−/− and WT mice who underwent CCI at both time points. *P < 0.05, **P < 0.01. ‘ns’ denotes not statistically
different, Kruskal-Wallis ANOVA on ranks followed by Dunn's multiple comparison test (n = 4 to 6).
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AL-8810 treated-animals, whereas in the hippocampus,
Iba1 immunoreactivity was decreased to the control level
at this time point. The most significant improvement with
single and repeated AL-8810 treatment was observed in
the susceptible thalamic regions (Figure 5C).
To study reactive gliosis, we used GFAP immunoreactiv-
ity. Similar to a microglial marker, the GFAP levels were
considerably increased in the cortical penumbra, as well as
in the ipsilateral hippocampus and thalamic areas com-
pared with the corresponding contralateral areas in the
CCI-treated animals at both time points used in the study.
A small increase in the GFAP was observed in the cortical
area surrounding craniotomy in the sham WT animals,
and similar increases were observed in the sham- and
CCI-treated FP−/− mice (Figure 6A). No detectable differ-
ences in the GFAP immunoreactivities between ipsilateral
and contralateral hippocampus and thalamic regions were
observed in sham-operated WTanimals or in either sham-
or CCI-injured FP−/− mice. In the cortical penumbra and
hippocampus, the increase in the related GFAP immuno-
reactivities was observed at 48 hours, but not 10 days, after
injury, whereas in the thalamus, the increased immunore-
activity remained up to 10 days. The changes in GFAP
levels in the FP−/− mice were substantially lower compared
with the CCI-treated WT animals (Figure 6B). In FP−/−
mice, no significant changes in GFAP immunoreactivity
were detected in AL-8810 treatment groups compared
with the saline group following CCI (Figure 6C).Discussion
This study provides, for the first time, clarification of the
respective role of the calcium-modulating FP receptor as
a potential target for disease-modifying CNS drugs in
the treatment of acute brain injury. Our data demon-
strated significant anatomical and neurological improve-
ments following pharmacological blockade of the FP
receptor with a small-molecule-selective antagonist in a
preclinical CCI mouse model, suggesting the involve-
ment of this receptor in neuropathological consequences
of acute brain trauma. In WT mice, post-treatment with
AL-8810 following CCI significantly improved NDS and
ameliorated grip strength impairment following CCI,
and decreased CCI-induced hippocampal swelling and
the level of markers of gliosis and microglial activation
(that is, GFAP and Iba1) in susceptible brain regions
48 hours and 10 days following experimental brain in-
jury. Furthermore, morphological analyses of cerebral
vasculature and anastomoses in WT and FP−/− mice
confirmed that there are no differences between these
strains. In the FP−/− mice, the hippocampal swelling and
accumulation of astrocytic and microglial markers in the
brain were substantially lower than in WT mice, and
post-treatment with AL-8810 had no additional benefits
in FP−/− mice, indicating the selectivity of pharmaco-
logical action of this drug candidate on the FP receptor.
Importantly, the beneficial effects of FP antagonist were
achieved with a single systemic treatment, suggesting


















































































































Figure 5 Effects of genetic deletion and blockade of FP receptor on the ionized calcium-binding adapter protein 1 (Iba1) expression
after controlled cortical injury (CCI). (A and B) Representative photographs of Iba1 immunohistochemistry on hippocampal brain sections from
sham- and CCI-injured WT (A) and FP−/− (B)mice 48 hours after injury. Rectangular selections in the inserts denote magnified regions. (C) Bar graph
represents quantitative analysis of Iba1 immunoreactivity in cortical penumbra, hippocampus, and thalamus in saline- and AL-8810- (10 mg/kg) treated
WT and FP−/− mice that underwent CCI or sham 48 hours and 10 days following injury. All data are normalized to the corresponding value of the
contralateral side. Data are presented as mean ± SEM, *P < 0.05, **P < 0.01 versus saline-treated WT sham-operated animals, #P < 0.05, ##P < 0.01, versus
saline-treated WT CCI group, one-way ANOVA followed by Tukey's multiple comparison test (n = 3 to 7).
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of TBI.
Our previous data suggested a potential therapeutic role
for PGF2α FP receptor blockade in preclinical ischemic
stroke models [21,22]. Despite different epidemiology and
etiologies of stroke and TBI, both conditions share many
common pathophysiological features, including formation
of ischemic penumbra and brain edema [32]. TBI is a com-
plex disorder that causes brain damage through several
coexisting mechanisms, including primary and secondary
excitotoxicity, ischemia, brain hemorrhage, and after tox-
icity that has been caused by hemoglobin breakdown prod-
ucts, diffuse edema, and upregulation of proinflammatory
mediators [33]. Vascular damage plays an important role
in TBI and is a primary cause of hemorrhage in different
brain regions to the extent correlated with TBI severity
[34], extensive glutamate release [35], and cortical necrosis
[34]. The hemorrhagic component itself could trigger sec-
ondary biochemical cascades, exacerbating primary brain
damage involving oxygen free radicals, membrane lipidperoxidation, glutamate receptor upregulation, and excito-
toxicity [36,37]. Neuroinflammatory pathways involving
COX-2 upregulation have been considered to be involved
with pathological sequelae of TBI [12,13]. Experimental re-
ports and clinical data suggest that COX-2 upregulation
and subsequent increases in the levels of several classes of
prostaglandins, notably PGF2α, are involved in numerous
neurological disorders. In mammalians, expression of the
FP receptor has been demonstrated in whole brain homog-
enates [38], brain synaptosomes [39], and cerebral micro-
vessels [40]. In addition, it has been reported that the FP
receptor is expressed in cultured cortical neurons [41] and
astrocytes [42].
The role of the FP receptor in the brain is not well
understood. It has been shown that this receptor is in-
volved differently in the pathological pathways in animal
models of stroke [21,22] and seizures [43]. In addition,
PGF2α induces cerebral vasoconstriction in adults and
newborns, though in the latter case to a substantially





































































































































Figure 6 Effects of genetic deletion and blockade of FP receptor on the glial fibrillary acidic protein (GFAP) expression after controlled
cortical injury (CCI). (A and B) Representative photographs of GFAP immunohistochemistry on hippocampal brain sections from sham- and
CCI-injured WT (A) and FP−/− (B) mice 48 hours after injury. Rectangular selections in the inserts denote magnified regions. (C) Bar graph
represents quantitative analysis of GFAP immunoreactivity in cortical penumbra, hippocampus, and thalamus in saline- and AL-8810- (10 mg/kg)
treated WT and FP−/− mice that underwent CCI or sham 48 hours and 10 days following injury. All data are normalized to the corresponding
value of the contralateral side. Data are presented as mean ± SEM, ***P < 0.001 versus saline-treated WT sham group, #P < 0.05, ##P < 0.01, versus
saline-treated WT CCI group, one-way ANOVA followed by Tukey's multiple comparison test (n = 3 to 7).
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with stroke and subarachnoid hemorrhage when samples
were collected shortly after the cerebral attack, which
then decreased with the regression of clinical symptoms
[46,47]. However, other studies found no relationship be-
tween PGF2α level in lumbar CSF and neurological def-
icit [48]. Experimental study further suggests that the
PGF2α concentration in lumbar CSF might not reflect its
intracranial level depending on the size and location of
the hemorrhage [47]. Clinical data indicate the COX-2
upregulation in hippocampal biopsies from patients with
therapy-refractive temporal lobe epilepsy [49], which is
consistent with the previous findings of increased con-
centrations of PGF2α in the CSF of epilepsy patients
[46,50]. Increased CSF PGF2α levels have also been ob-
served in infants and children with febrile convulsions
[51], which have been recently proposed as a risk factor
for development of temporal lobe epilepsy [52,53]. Other
evidence supporting the proconvulsive properties ofPGF2α include several cases of seizures and abnormal
electroencephalographic changes associated with the
clinical use of PGF2α analogs to terminate pregnancy
that have been reported in clinical practice [54-57].
Nevertheless, action PGF2α is disputed and the FP recep-
tor role still remains controversial [58]. Several contrary
experimental reports demonstrated that administration of
PGF2α caused seizure aggravation [59] and abolished the
anticonvulsant effects of other prostaglandins [60,61],
whereas others suggested that elevated levels of PGF2α
might have anticonvulsant action [43,62]. The level of ara-
chidonic acid, a precursor of prostaglandin synthesis, sig-
nificantly increases in the cortex and hippocampus after
CCI in rodents, and it has been suggested that arachidonic
acid metabolites, including PGF2α, may play a role as me-
diators in the blood–brain barrier breakdown [63,64],
which might be associated with edema formation in TBI
[65]. On the molecular level, activation of the FP receptor
initiates several events, including stimulation of the
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2+ signaling pathway [6,21]. By
this means, supraphysiological levels of PGF2α may poten-
tially lead to intracellular calcium overload [21], which
could consequently lead to excessive release of excitatory
neurotransmitters, or could even trigger neuronal necrosis
via activation of calpains [66].
In this study, we used male WT and FP−/− mice of the
same C57BL/6 background. Strain-dependent differences
in the response to the experimental brain trauma have
been reported in rats [67,68] and mice [69,70]. Some
studies in mouse stroke models have demonstrated that
strain-dependent differences in cerebrovascular anat-
omy are associated with susceptibility to cerebral ische-
mia [30], although others suggest an involvement of
intrinsic genetic determinants in ischemia and glutam-
ate excitotoxicity-induced cell death [28,71]. Our previ-
ous data, obtained in an ischemia model, indicated that
genetic deletion of the FP receptor does not affect the
vital physiological parameters in mice. No substantial
differences in cerebral blood flow, body temperature,
mean arterial blood pressure, blood gases (PaO2,
PaCO2), or pH between WT and FP
−/− mice were ob-
served before, during stroke, or after reperfusion [22].
This study also demonstrated no significant differences in
anastomoses of two major cerebral arteries. Taken together,
these data suggest that differences between anatomical and
neurological outcomes between WTand FP−/− mice are as-
sociated with the FP receptor deletion.
In this study, AL-8810 significantly improved anatom-
ical and neurological outcomes in a preclinical TBI
model. It is well known that regional vulnerability of the
brain is characteristic for TBI. In unilateral TBI models
performed in adult animals, neuronal damage is mostly
located in the cortex and hippocampus of the ipsilateral
hemisphere, whereas in immature animals, significant
neuronal loss is more widespread and includes ipsilateral
hippocampus and ipsilateral thalamus, as well as the ip-
silateral and the contralateral cortices compared to sham
[72]. A noticeable hippocampal swelling was also ob-
served 48 hours and 10 days after CCI in saline-treated
animals. The decrease in the CCI-induced hippocampal
swelling in animals post-treated with AL-8810 suggests
involvement of the FP receptor in edema formation fol-
lowing brain trauma. One of the possible mechanisms is
that overactivation of the FP receptor promotes the
blood–brain barrier breakdown and aggravates edema
formation [63,64]. Brain edema starts within minutes
after TBI, and becomes progressively more severe over
time, peaks at 24 hours after injury, and begins to de-
cline after the third day [73,74]. Based on the increase in
water content and Evans blue dye extravasation in the
injured ipsilateral cortex and hippocampus, it has been
suggested that the blood–brain barrier opening after
CCI is biphasic [75]. The first blood–brain barrierbreakdown occurs within four and six hours, and the
second opening occurs on the third day after injury in
the ipsilateral cortex and hippocampus [73]. However,
the second opening of the blood–brain barrier does not
contribute to a further increase in edema formation [73].
Our data indicating that repeated AL-8810 treatment
provides no additional benefits compared with a single
AL-8810 post-treatment is consistent with the putative
role of only the first blood–brain barrier breakdown in
edema development. Furthermore, these data suggest
that the blockade of the FP receptor with a small-
molecule antagonist at early time points might be an ef-
fective treatment for brain edema in TBI.
In addition, significant improvement in NDS and grip
strengths were observed in the AL-8810-treated group
compared with saline-treated animals. The improve-
ments in NDS were dependent on AL-8810 dosage. The
treatment was effective when the drug was administered
following CCI at single dose, and additional AL-8810 in-
jection did not cause significant improvement in NDS
compared with single dosage. The grip strength test is
included in the functional observational battery for use
in the neurotoxicity studies in rodents to access neuro-
motor function [76]. In addition, clinical data indicate
that grasping is impaired in children after TBI [77], and
the quantitative analysis of precision-grip forces has
been proposed as a sensitive method to assess recovery
of fine motor skills [77,78]. Our data indicate a signifi-
cant decrease in grip strength following CCI, and the de-
crease in grip strength was three-fold less in the
AL-8810-treated group, which suggests that the FP re-
ceptor blockade might protect neuromotor function or
facilitate its recovery following CCI.
Another important finding of this study is that ana-
tomical brain injury is significantly reduced in FP−/−
mice. Interestingly, the anatomical improvement was not
associated with the acute neurological outcome observed
in AL-8810-treated WT mice. This finding suggests a
dual role for the FP receptor in TBI recovery, and that
activation of this receptor, at some level, might be bene-
ficial for short-term outcomes. On the other hand, the
beneficial effect of AL-8810 in WT mice could be ex-
plained by the unique pharmacological properties of this
compound. In the studies performed in different cell
lines, AL-8810, in addition to its antagonist properties,
has been shown to be a partial agonist with approxi-
mately 20% efficacy at the endogenous FP receptor [23].
Although the FP receptors play important roles in dif-
ferent systems of mammalian organism overall, with a
few exceptions, the effects of the FP receptor activation
are believed to be pathophysiological; thus, more close
attention may be paid to development of FP receptor
antagonists as promising agents for treatment of diverse
acute and chronic conditions, including preterm labor,
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Our data presented here indicate that a single treatment
with AL-8810 applied immediately after CCI was suffi-
cient to produce a beneficial effect on neurological out-
come. Surprisingly, NDS outcomes after experimental
TBI were not affected in FP−/− mice compared to WT
mice, indicating that the FP receptor may play a role in
some aspects of neural behavior. This finding is in con-
trast with published data from our group obtained in
stroke models where genetic deletion of the FP receptor
improved neurobehavioral outcomes in models of ische-
mic stroke and excitotoxicity [21,22]. On the other hand,
the published data with the prostaglandin E2 EP1 recep-
tor, which has a similar structure and functions as the
FP receptor [6,7,79], suggest that the effects of pharma-
cological blockade or genetic deletion of the EP1 receptor
might be opposite in ischemic and hemorrhagic stroke
[8,80-82]. Thereby, lack effect of FP knockout in TBI
might be explained by the complexity of its pathology,
which also includes a hemorrhagic component. Our data
also suggest that resolving of acute hippocampal edema
and gliosis, assessed by GFAP immunohistochemistry, lead
to functional recovery and reduction of delayed inflamma-
tion and microglia activation in susceptible brain regions
assessed by Iba1 immunohistochemistry. Thus, thera-
peutic strategy with a single-dose treatment would be op-
timal to obtain beneficial effects and minimize possible
side effects in clinical applications.
In this study, significant improvements in the levels of
microglial activation and reactive gliosis, assessed immu-
nohistochemically, were detected in the selected brain
regions of FP−/− mice and WT mice that underwent
treatment with AL-8810 following experimental TBI. In
addition, in the FP−/− mice, AL-8810 did not cause de-
tectable changes in the Iba1 and GFAP immunoreactiv-
ities compared with saline (Additional file 1: Figure S1,
B and C). Interestingly, similar beneficial effects of
AL-8810 were observed with single and repeated treat-
ment. Although further detailed studies are warranted
to determine the exact therapeutic window of adminis-
tration for the FP receptor antagonist in treatment of
TBI, the data in the literature indicate that the upregu-
lation of the inducible COX-2 enzyme occurs within
several hours [12,14-16] and that the increased levels of
the prostaglandin precursor remained for several days
following brain trauma [18], suggesting a potential clin-
ical application for prospective drugs in critical care. It
is important to note that the role of COX-2 in brain in-
jury is complex [15,16] and that the FP receptor antag-
onist selectively targets a downstream proinflammatory
cascade of cyclooxygenase, leaving intact potentially
neuroprotective ones. For example, we and others have
previously shown that pathways involving prostaglandin
PGE2 receptors EP2 and EP4 were demonstrated inpreclinical excitotoxic and ischemic animal models
[81,83,84].
Conclusions
This study suggests that the PGF2α FP receptor is involved
in neuroinflammatory pathways and contributes to the
overall pathology of brain trauma, and taking into account
the similarity of prostaglandin drugs used in the clinic, se-
lective FP antagonists could be used therapeutically in
acute brain insult. Our findings provide a novel target for
the treatment of TBI and help to elucidate the therapeutic
potential and role of the FP receptor in acute brain trauma
that will lead to more efficient and safe therapies; thus im-
proving the quality of life of TBI patients for which effect-
ive treatment is currently unavailable.
Additional file
Additional file 1: Figure S1. Lack of effects of AL-8810 post-treatment
on brain pathology, gliosis, and microglia activation after sham surgery.
(A) Representative photographs of bran sections from sham-injured WT
mice post treated with a single dose of AL-8810 (10 mg/kg) 10 days after
surgery stained with cresyl violet (A), and DAB immunostained for GFAP (B)
and Iba1 (C). Top panels: examples of four brain sections cut throughout
the entire craniotomy area. Middle panels: photographs of the stained and
immunostained brain sections cut between 1 and 2 mm posterior from
bregma zoomed in to demonstrate ipsilateral and contralateral susceptible
brain regions (that is, cortical penumbra, hippocampus, and lateral dorsal
and posterior nuclei of the thalamus). Bottom panels: zoomed area
photographs presented in middle panels to demonstrate CA1 region of
hippocampus, corpus callosum, and cortex in thinner details. Similar to
saline-treated sham animals, no differences were observed between
ipsilateral and contralateral sides in sham mice post-treated with AL-8810.
The presented data is representative for a group of four mice.
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